Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery
- PMID: 32902689
- DOI: 10.1007/s00701-020-04537-w
Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery
Abstract
Introduction: The effects of single-fraction gamma knife radiosurgery (sf-GKRS) on patients with renal cell carcinoma (RCC) brain metastases (BM) in the era of targeted agents (TA) and immune checkpoint inhibitors (ICI) are insufficiently studied.
Methods and materials: Clear cell metastatic RCC patients treated with sf-GKRS due to BM in 2005-2014 at three European centres were retrospectively analysed (n = 43). Median follow-up was 56 months. Ninety-five percent had prior nephrectomy, 53% synchronous metastasis and 86% extracranial disease at first sf-GKRS. Karnofsky performance status (KPS) ranged from 60 to 100%. Outcome measures were overall survival (OS), local control (LC) and adverse radiation effects (ARE).
Results: One hundred and ninety-four targets were irradiated. The median number of targets at first sf-GKRS was two. The median prescription dose was 22.0 Gy. Thirty-seven percent had repeated sf-GKRS. Eighty-eight percent received TA. LC rates at 12 and 18 months were 97% and 90%. Median OS from the first sf-GKRS was 15.7 months. Low serum albumin (HR for death 5.3), corticosteroid use pre-sf-GKRS (HR for death 5.8) and KPS < 80 (HR for death 9.1) were independently associated with worse OS. No further prognostic information was gleaned from MSKCC risk group, synchronous metastasis, age, number of BM or extracranial metastases. Other prognostic scores for BM radiosurgery, including DS-GPA, renal-GPA, LLV-SIR and CITV-SIR, again, did not add further prognostic value. ARE were seldom symptomatic and were associated with tumour volume, 10-Gy volume and pre-treatment perifocal oedema. ARE were less common among patients treated with TA within 1 month of sf-GKRS.
Conclusions: We identified albumin, corticosteroid use and KPS as independent prognostic factors for sf-GKRS of clear cell RCC BM. Studies focusing on the prognostic significance of albumin in sf-GKRS are rare. Further studies with a larger number of patients are warranted to confirm the above analytical outcome. Also, in keeping with previous studies, our data showed optimal rates of local tumour control and limited toxicity post radiosurgery, rendering GKRS the tool of choice in the management of RCC BM.
Keywords: GKRS; Gamma knife; RCC; Renal cell carcinoma; SRS; Stereotactic radiosurgery.
Similar articles
-
Improving the Prognostic Value of Disease-Specific Graded Prognostic Assessment Model for Renal Cell Carcinoma by Incorporation of Cumulative Intracranial Tumor Volume.World Neurosurg. 2017 Dec;108:151-156. doi: 10.1016/j.wneu.2017.07.109. Epub 2017 Jul 25. World Neurosurg. 2017. PMID: 28754641 Free PMC article.
-
Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery.J Neurooncol. 2021 Jul;153(3):527-536. doi: 10.1007/s11060-021-03793-9. Epub 2021 Jun 25. J Neurooncol. 2021. PMID: 34170460
-
Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401).J Neurosurg. 2016 Dec;125(Suppl 1):11-17. doi: 10.3171/2016.7.GKS161459. J Neurosurg. 2016. PMID: 27903179
-
Fractionated Gamma Knife radiosurgery after cyst aspiration for large cystic brain metastases: case series and literature review.Neurosurg Rev. 2022 Oct;45(5):3457-3465. doi: 10.1007/s10143-022-01835-y. Epub 2022 Jul 14. Neurosurg Rev. 2022. PMID: 35834076 Review.
-
Global management of brain metastasis from renal cell carcinoma.Crit Rev Oncol Hematol. 2022 Mar;171:103600. doi: 10.1016/j.critrevonc.2022.103600. Epub 2022 Jan 19. Crit Rev Oncol Hematol. 2022. PMID: 35063636 Review.
Cited by
-
Stereotactic radiosurgery for fourth ventricle brain metastases: tumor control outcomes and the need for CSF diversion. Patient series.J Neurosurg Case Lessons. 2024 Nov 25;8(22):CASE24293. doi: 10.3171/CASE24293. Print 2024 Nov 25. J Neurosurg Case Lessons. 2024. PMID: 39586085 Free PMC article.
-
Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies.Front Oncol. 2022 Mar 2;12:854402. doi: 10.3389/fonc.2022.854402. eCollection 2022. Front Oncol. 2022. PMID: 35311078 Free PMC article. Review.
References
-
- Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665–1672 - PubMed
-
- Angelov L, Mohammadi AM, Bennett EE et al (2018) Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥2 cm. J Neurosurg 129(2):366–382 - PubMed
-
- Auchter RM, Lamond JP, Alexander E et al (1996) A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 35(1):27–35 - PubMed
-
- Barata PC, Mendiratta P, Kotecha R et al (2018) Effect of switching systemic treatment after stereotactic radiosurgery for oligoprogressive, metastatic renal cell carcinoma. Clin Genitourin Cancer 16(5):413–419 - PubMed
-
- Calvo E, Porta C, Grünwald V, Escudier B (2019) The current and evolving landscape of first-line treatments for advanced renal cell carcinoma. Oncologist 24(3):338–348 - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical